Skip to main navigation Skip to search Skip to main content

The development of activating and inhibiting camelid VHH domains against human protein kinase C epsilon

  • M.M.I. Paalanen
  • , E. Ekokoski
  • , M. El Khattabi
  • , R.K. Tuominen
  • , C.T. Verrips
  • , J. Boonstra
  • , C.F.J. Blanchetot
  • extern

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The 10 isozymes of the protein kinase C (PKC) family can have different roles on the same biological process, making isozyme specific analysis of function crucial. Currently, only few pharmacological compounds with moderate isozyme specific effects exist thus hampering research into individual PKC isozymes. The antigen binding regions of camelid single chain antibodies (VHHs) could provide a solution for obtaining PKC isozyme specific modulators. In the present study, we have successfully selected and characterized PKCɛ specific VHH antibodies from two immune VHH libraries using phage display. The VHHs were shown to exclusively bind to PKCɛ in ELISA and immunoprecipitation studies. Strikingly, five of the VHHs had an effect on PKCɛ kinase activity in vitro. VHHs A10, C1 and D1 increased PKCɛ kinase activity in a concentration-dependent manner (EC50 values: 212–310 nM), whereas E6 and G8 inhibited PKCɛ activity (IC50 values: 103–233 nM). None of these VHHs had an effect on the activity of the other novel PKC isozymes PKCδ and PKCθ. To our knowledge, these antibodies are the first described VHH activators and inhibitors for a protein kinase. Furthermore, the development of PKCɛ specific modulators is an important contribution to PKC research.
Original languageEnglish
Pages (from-to)332-339
Number of pages8
JournalEuropean Journal of Pharmaceutical Sciences
Volume42
Issue number4
Publication statusPublished - 18 Mar 2011

Fingerprint

Dive into the research topics of 'The development of activating and inhibiting camelid VHH domains against human protein kinase C epsilon'. Together they form a unique fingerprint.

Cite this